Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02150070 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

A Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP2408, sponsored by Astellas Pharma Global Development.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT02150070: Completed Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP2408, sponsored by Astellas Pharma Global Development.

NCT02150070 is a Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP2408 that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 32 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02150070, a Phase 1 study of Healthy Subjects and Pharmacokinetics of ASP2408, has completed, sponsored by Astellas Pharma Global Development.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of subcutaneous (SC) injections of the same clinical trial material.

Primary Outcome

Area under the concentration - Time curve from time 0 up to the last quantifiable concentration (AUClast)

Interventions

  • DRUG Placebo
  • DRUG ASP2408

Study Locations (1)

Maryland

  • Parexel International - Baltimore

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2011-08
Est. Completion 2012-06
Phase Phase 1
Astellas Pharma Global Development

168 total trials

What the finished NCT02150070 record still lists

NCT02150070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower).

The record links to 2 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02150070 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT02150070 about?

NCT02150070 is a clinical study titled "A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections". The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of subcutaneous (SC) injections of the same clinical trial material.

What is the current status of trial NCT02150070?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-08. Estimated completion is 2012-06.

What conditions does trial NCT02150070 study?

This clinical trial studies the following conditions: Healthy Subjects, Pharmacokinetics of ASP2408.

What interventions are being tested in trial NCT02150070?

The interventions under investigation include: Placebo (DRUG), ASP2408 (DRUG).

Who is sponsoring clinical trial NCT02150070?

This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02150070 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Subjects

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02150070's enrollment target sits among peer trials

32 35th of 69 higher than 33 of 69 other Healthy Subjects trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02150070, the US trial registry maintained by the National Library of Medicine. NCT02150070 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.